• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Gilead inks $90m deal with Verily to create “molecular map” of inflammatory disease

May 1, 2018 By Sarah Faulkner

Gilead SciencesGilead Sciences (NSDQ:GILD) is reportedly slated to pay Alphabet’s Verily Life Sciences $90 million over three years to analyze cells from patients with rheumatoid arthritis, inflammatory bowel disease and lupus-related diseases.

By probing immune cells from patients involved in Gilead’s clinical trials, the companies hope to glean a better understanding of the immunological signatures of RA, IBD and lupus-related diseases. It’s the first large-scale use of Verily’s Immunoscape platform, which combines immunogenomic phenotyping and computational analysis to profile the molecular characteristics of inflammatory diseases.

The companies’ collaboration could produce new knowledge about the biology of RA, IBD and lupus-related diseases, Gilead said. Ultimately, the group hopes to help doctors select a therapy or dosing that is specific to particular groups of patients.

“Inflammatory diseases are complex and heterogeneous, and despite treatment advances, most patients experience neither deep nor long-lasting remissions,” Dr. John McHutchison, chief scientific officer and head of R&D at Gilead, said in prepared remarks. “We hope to ultimately improve patient outcomes using this cutting-edge technology to identify molecular disease pathways that would otherwise remain undetected.”

“With the Immunoscape platform, we are seeking to develop a molecular map of inflammatory diseases that will help us identify and characterize disease mechanisms,” Dr. Jessica Mega, chief medical officer at Verily, added. “This collaboration with Gilead is an incredible opportunity to learn much more about these immune-mediated conditions than ever before, and to hone in on potential paths to deliver more precise medicine to patients.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Diagnostics, Discovery, Drug-Device Combinations, Featured, Immunotherapy, Pharmaceuticals, Wall Street Beat Tagged With: Gilead Sciences, Verily

IN CASE YOU MISSED IT

  • Senseonics stock is up on Q2 results
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS